文献速递免疫规划慢病防控与筛查

儿童期接种HPV疫苗女性CIN2+的HPV基因型分布:Trial23队列研究

Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study.
PubMed 文献 · Vaccine · 2025-12-23

丹麦Trial23队列纳入15,668名1994年出生女性,95%接种四价HPV疫苗。接种者CIN2+发病率为5.3/1000人年,未接种者为12.1/1000人年(HR 0.44)。疫苗对HPV16/18相关CIN2+保护率达95%,但非疫苗高危型仍有相当负担,提示需调整筛查策略。

要点

  • 接种四价HPV疫苗使CIN2+总体风险降低56%(HR 0.44)。
  • HPV16/18相关CIN2+风险降低95%(HR 0.05)。
  • 非疫苗高危型HPV相关CIN2+仍构成相当疾病负担。

核心结论

  • HPV16/18疫苗接种显著降低HPV16/18相关CIN2+风险,但非疫苗高危型仍带来相当负担。
  • 接种女性CIN2+的HPV基因型分布发生改变,提示需调整筛查策略。

研究设计与样本

  • 基于丹麦Trial23队列的 population-based 队列研究,纳入15,668名1994年出生女性,2008年接种四价HPV疫苗,2017年进入筛查年龄,随访超过7年。
  • 队列中95%接种疫苗、5%未接种;主要终点为HPV型别特异性新发CIN2+,取2017–2023年首次CIN2+活检样本用Seegene Allplex HPV28进行基因分型。
  • 采用Cox比例风险模型按层级分组HPV基因型估计CIN2+的HR。

主要发现

  • 接种女性CIN2+发病率为5.3/1000人年,未接种女性为12.1/1000人年(HR 0.44;95%CI 0.34–0.57)。
  • HPV16/18相关CIN2+风险降低95%(HR 0.05;95%CI 0.03–0.09)。
  • HPV31/33/45/52/58相关CIN2+风险降低32%,但无统计学显著性(调整HR 0.68;95%CI 0.43–1.09)。
  • 其他高危HPV型相关CIN2+的HR为0.70(95%CI 0.35–1.37)。

临床怎么用

  • 接种HPV疫苗女性仍需接受宫颈筛查,因非疫苗高危型HPV相关CIN2+负担持续存在。
  • 筛查策略应考虑接种女性CIN2+的HPV基因型分布变化,可能需要调整型别检测或分流方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of prophylactic HPV vaccination has significantly reduced vaccine-type HPV infections and is reshaping the landscape of cervical cancer prevention. As vaccinated cohorts enter screening age, understanding the genotype-specific risk of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) is critical for adapting screening strategies. AIM: To compare HPV genotype-specific detection rates of histologically confirmed CIN2+ between vaccinated and unvaccinated women in Denmark's Trial23 cohort, with over seven years of follow-up. METHOD: This population-based cohort study included 15,668 women born in 1994 who were offered HPV vaccination with the 4-valent vaccine in 2008 and entered Danish screening age in 2017 In our cohort, 95 % were vaccinated and 5 % were unvaccinated. The primary endpoints of this study were HPV-type-specific incident CIN2+ cases. The first histological biopsy sample diagnosed with CIN2+ in 2017-2023 was retrieved for HPV genotyping with the Seegene Allplex HPV28. Cox proportional hazards models estimated hazard ratios (HRs) for CIN2+ outcomes by hierarchically grouped HPV genotypes. RESULTS: Among vaccinated women, the incidence of CIN2+ was 5.3 per 1000 person-years, compared to 12.1 per 1000 person-years in unvaccinated women (HR: 0.44; 95 % CI: 0.34-0.57). Vaccination was associated with a 95 % reduction in HPV16/18-related CIN2+ (HR: 0.05; 95 % CI: 0.03-0.09). A similar, but non-significant, trend of a 32 % risk of CIN2+ for HPV31/33/45/52/58 was found, with an adjusted HR of 0.68 (95 % CI: 0.43-1.09). For CIN2+ associated with other high-risk HPV types, the HR was 0.70 (95 % CI 0.35-1.37). CONCLUSION: HPV16/18 vaccination reduced the risk of HPV16/18-related CIN2+ lesions, but a substantial burden remained from non-vaccine high-risk types. The substantial protection against HPV16/18-related CIN2+ and the consequential shift in HPV genotype distribution of CIN2+ among vaccinated women underline the need for adaptation of screening strategies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Nonboe MH, Napolitano G, Schroll JB, et al. Human papillomavirus genotype distribution in cervical intraepithelial neoplasia grade 2+ from childhood vaccinated women: The Trial23 cohort study. Vaccine. 2025. PMID: 41442869. doi:10.1016/j.vaccine.2025.128142

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。